Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if DNLI is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
38 top institutions tracked
Last 13F trend: distributing (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 35 days ago
Red flags: 0
293 filers reported a long position in DNLI for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | $416.1M | 16.2M | +89.9% |
| BlackRock, Inc. | $360.8M | 14M | +7.6% |
| BAILLIE GIFFORD & CO | $307.6M | 12M | -0.9% |
| STATE STREET CORP | $181.3M | 7M | +12.4% |
| Temasek Holdings (Private) Ltd | $180.4M | 7M | Unchanged |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $166.6M | 6.5M | +5.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | $161.4M | 6.3M | +2.1% |
| FMR LLC | $116.7M | 4.5M | -0.9% |
| GOLDMAN SACHS GROUP INC | $106.9M | 4.2M | -5.7% |
| GEODE CAPITAL MANAGEMENT, LLC | $102.2M | 4M | +6.6% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.